Environmental contamination of drinking water with chromium (Cr) has been increasing in more than 30 cities in the United States. Previous studies from our group have shown that Cr affects reproductive functions in female Sprague Dawley rats. Although it is impossible to completely remove Cr from the drinking water, it is imperative to develop effective intervention strategies to inhibit Cr-induced deleterious health effects. Edaravone (EDA), a potential inhibitor of free radicals, has been clinically used to treat cancer and cardiac ischemia. This study evaluated the efficacy of EDA against Cr-induced ovarian toxicity. Results showed that maternal exposure to CrVI in rats increased follicular atresia, decreased steroidogenesis, and delayed puberty in F1 offspring. CrVI increased oxidative stress and decreased antioxidant (AOX) enzyme levels in the ovary. CrVI increased follicle atresia by increased expression of cleaved caspase 3, and decreased expression of Bcl2 and Bcl2l1 in the ovary. EDA mitigated or inhibited the effects of CrVI on follicle atresia, pubertal onset, steroid hormone levels, and AOX enzyme activity, as well as the expression of Bcl2 and Bcl2l1 in the ovary. In a second study, CrVI treatment was withdrawn, and F1 rats were injected with estradiol
INTRODUCTION
Hexavalent chromium (CrVI) has been used in various industries such as leather and textiles, metallurgical, chemical, and automobile [1] [2] [3] . Because of increased use and improper disposal of CrVI, its levels in the water, soil, and air continue to increase [4] [5] [6] . Significant contamination with CrVI has been found in the drinking water sources of more than 30 cities in the United States, including cities in Oklahoma and California [7] . According to the Environmental Protection Agency (EPA) report in February 2014, well water from Midland, Texas, contains 5.28 ppm chromium (Cr) [8] . The California EPA has set maximum contamination level for Cr as 100 ppb or 0.1 ppm [9] . Occupational exposure to CrVI is found among approximately one-half million industrial workers in the United States and several million worldwide [10] . CrVI is known to cause various health problems, including infertility in men and women and developmental problems in children [11] . Women working in dichromate manufacturing industries and tanneries and living around Cr-contaminated areas have high levels of Cr in blood and urine and encounter gynecological illness, abortion, postnatal hemorrhage, and birth complications [12] [13] [14] [15] . Our recent study demonstrated that maternal exposure to trivalent Cr (CrIII) accelerates follicle atresia through elevated oxidative stress [16] . Although Cr is known to adversely affect reproductive health in women [17] , the specific mechanisms of reproductive toxicity are not clearly understood.
At physiological pH, CrVI exists in the form of an oxyanion with an overall 2 À charge that resembles sulfate and phosphate, and CrVI is taken up by cells via the anionic transport system [18, 19] . This transport system, along with intracellular reduction reactions, allows Cr to accumulate in cells at concentrations that are much higher than extracellular levels [20, 21] . Once CrVI enters the cell, it is reduced to CrIII by various intracellular reductants [22, 23] . During the intracellular reduction process of CrVI to CrIII, a spectrum of reactive oxygen species (ROS) (i.e., superoxide [ O 2 ] , and hydroxyl radical [ OH] ) is produced [24] , with the depletion of antioxidant (AOX) enzymes such as superoxide dismutase (Sod1), glutathione peroxidase (Gpx1), and catalase (Cat) resulting in oxidative stress [25] . Oxidative stress has been proposed as a major pathway of Cr toxicity [24] . Thus, reduction of ROS generation within cells is expected to reduce or prevent Cr toxicity.
Given the fact that usage of Cr has been exponentially increasing both in the United States and in developing countries, and that environmental Cr contamination is one of the greatest threats to human health because of difficulties in removing Cr from the soil and water, it is imperative to develop potential intervention strategies. We previously reported that vitamin C protects F1 offspring subjected to CrIII exposure through lactation during Postnatal Days (PND) 1-21 [16, 26, 27] . Follicular atresia and granulosa cell (GC) apoptosis in offspring were blocked by inhibiting cell death pathways [27] and promoting cell survival and/or cell growth pathways [16] . In furthering improved intervention strategies designed to protect the ovary against Cr toxicity, we tested the hypothesis that cotreatment of edaravone (EDA) with CrVI or posttreatment of estradiol (E 2 ) after postnatal exposure to CrIII protects the ovary against CrIII toxicity in F1 offspring.
EDA (3-methyl-1-phenyl-2-pyrazolin-5-one; MCI-186) is a potent, low-molecular-weight, free-radical scavenger that has 
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FIG. 3.
Effects of maternal exposure to CrVI on pubertal onset and serum steroid hormone levels. Lactating dams were divided into three groups: control, rats (n ¼ 5) received regular drinking water; CrVI, rats (n ¼ 5) received CrVI (50 ppm) in drinking water; and CrVI þ EDA, rats (n ¼ 5) received CrVI (50 ppm) in drinking water and EDA (15 mg/kg body wt., i.p., daily injections). Suckling F1 female offspring (n ¼ 20) received Cr through dam's milk during PND 1-21. On PND 25, ovaries were harvested, paraffin-embedded sections were stained with H&E, and atretic (primordial, primary, secondary, and antral) follicle numbers were counted. Serum levels of steroid hormones E 2 , P4, and T were measured on PND 25 in F1 female pups. Another set of the rats from the above groups was maintained in regular drinking water and diet until pubertal onset. Mitigative effect of EDA on CrVI-induced delay in pubertal onset (A) and decrease in E 2 (B), P4 (C), and T (D) are shown. Data are presented as mean 6 SEM. *Control versus CrVI, P , 0.05. EDARAVONE PROTECTS THE OVARY FROM CrVI TOXICITY been clinically used to reduce the neuronal damage following ischemic stroke [28] . It has been shown to quench OH, peroxynitrite (ONOO À ), and both water-soluble and lipidsoluble peroxyl radical (LOO ) [28, 29] . EDA is widely distributed in tissues and readily crosses the blood-brain barrier [30] . In addition to its effects on OH removal, EDA modulates inflammatory processes, matrix metalloproteinase levels, nitric oxide production, and both apoptotic and necrotic cell death [31] . EDA provides neuroprotection from traumatic brain injury [32] and cerebral infarction [33] and ameliorates several neurological diseases such as Parkinson [34] and Alzheimer diseases [35] . It has also been approved as a treatment for acute ischemic stroke [28, 36] . In a rat coronary occlusion model, EDA reduced the myocardial infarction area, maintained myocardial ATP content, decreased mitochondrial swelling, reduced cytochrome c release, increased the expression of Bcl2, and reduced the number of apoptotic cells and DNA fragmentation [37] . To the best of our knowledge, the protective effects of EDA have not been studied in the ovary. Moreover, our recent [16] and current studies suggest CrIII induces a decrease in E 2 levels that accompany depletion of AOX enzymes. Therefore, the purpose of the current study was twofold: first, to evaluate efficacy of EDA against the adverse effects of CrIII in F1 offspring, and second, to evaluate the ability of E 2 to restore the CrIII-induced decrease in AOX enzymes.
MATERIALS AND METHODS
Chemicals
Reagents, supplies, and primary antibodies used in this study are listed in Supplemental Tables S1 and S2 (Supplemental Data are available online at www.biolreprod.org).
Animals
Timed pregnant Sprague-Dawley rats were purchased from Charles River Laboratories and maintained in Association for Assessment and Accreditation of Laboratory Animal Care-approved animal facilities with a 12L:12D regime at 23-258C and provided with Teklad 6% mouse/rat diet and water ad libitum. Animal use protocols were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals, were in accordance with the standards established by Guiding Principles in the Use of Animals in Toxicology and specific guidelines and standards of the Society for the Study of Reproduction, and were approved by the Institutional Animal Care and Use Committee of Texas A&M University.
In Vivo Dosing and Experimental Design
Dose-Response Studies. Lactating rats were divided into the following seven groups and treated with various doses of CrVI in drinking water as follows: Rats from group 1 received regular drinking water, and rats from groups 2, 3, 4, 5, 6, and 7 received 5, 10, 25, 50, 100, and 200 ppm potassium dichromate (CrVI) in drinking water, respectively. On the day of birth, male pups were removed and the litters were culled to 4 female pups per dam; thus, each treatment group consisted of 5 dams (F0) and 20 F1 female pups. In cases where fewer than four female pups were delivered, additional pups were 
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fostered from other litters. In all experimental groups, the lactating dams received CrVI treatment in drinking water from the day of parturition to Day 21 postpartum. During this period, the F1 offspring received Cr through the dam's milk. Because CrVI is rapidly converted into CrIII in cells, tissues, and biological fluids, the Cr found in dam's milk is predominantly CrIII. On PND 25, female pups from four dams (n ¼ 20; 4 pups/dam) from each group were euthanized under CO 2 anesthesia followed by cervical dislocation, and blood and ovaries were collected. Effects of Cr on follicle atresia and apoptosis of oocytes and GCs were determined. Based on the effects of Cr on follicle atresia and the intensity of TUNEL-positive staining, a CrVI dose of 50 ppm was chosen to determine the ability of EDA to mitigate toxicity and the ability of E 2 to restore the Cr-induced decrease in AOX enzymes in the ovary.
Effects of EDA on CrVI Toxicity. Lactating dams were divided into the following three groups: 1) control: dams (n ¼ 5) received regular drinking water; 2) CrVI treatment: dams (n ¼ 5) received 50 ppm potassium dichromate dissolved in drinking water, 3) CrVI þ EDA treatment: dams (n ¼ 5) received 50 ppm CrVI with EDA (15 mg/kg body wt., i.p., daily injections). On the day of birth the litters were culled to 4 female pups per dam rat; thus, each treatment group consisted of 5 dams (F0) and 20 F1 female pups. CrVI doses were chosen based on dose-response studies as described above and drinking water levels of total Cr in the most polluted places in the United States and developing countries. Drinking water levels of Cr in Midland, TX, have been reported as 5.28 ppm [8] , and levels have been reported as 19-31 ppm in India [2, 38] . The EDA dose was chosen based on dose-response studies and literature using rodent models [39] [40] [41] . After weaning on PND 22, F1 female pups were fed with regular drinking water and diet. One group was euthanized on PND 25 and ovaries were collected and fixed in 4% buffered formaldehyde. Another group was maintained separately to observe pubertal onset by monitoring the vaginal opening [26] .
Effects of E 2 on CrVI-Induced Depletion of AOX Enzymes in the Ovary. In order to determine if E 2 could restore the ovary from Cr-induced oxidative damage, and depletion of AOX enzymes, the following experiments was conducted. Lactating dams were divided into three groups: 1) control: rats (n ¼ 5) received regular drinking water; 2) CrVI treatment: rats (n ¼ 5) received 50 ppm potassium dichromate (CrVI) dissolved in drinking water from the day of parturition until Day 21 postpartum; and 3) CrVI þ E 2 treatment: rats (n ¼ 5) received 50 ppm potassium dichromate (CrVI) dissolved in drinking water from the day of parturition until Day 21 postpartum. On the day of birth the litters were culled to 4 female pups per dam; thus, each treatment group consisted of 5 dams (F0) and 20 F1 female pups. On PND 22, F1 female pups were weaned from their dams, caged separately, provided with regular drinking water and diet, and divided into the following three groups: 1) control: on PND 25, F1 female rats (n ¼ 20) from control dams received only vehicle; 2) CrVI: F1 female rats (n ¼ 20) from CrVI-treated dams received only vehicle; and 3) CrVI þ E 2 treatment: F1 female rats (n ¼ 20) from CrVI-treated dams received E 2 for 2 wk from PND 25 through PND 39. Stock solution of E 2 was prepared in ethanol and diluted with sterile 13 PBS to prepare stock concentrations of 10 lg E 2 /100 ll PBS. Rats received i.p. injections of either vehicle (approximately 1 ll ethanol in 100 ll PBS) or E 2 (10 lg in PBS/ethanol per 100 g body weight) using a syringe equipped with a 28-gauge needle, and were euthanized on PND 40 for further analyses. At the end of the treatment, the rats were euthanized under CO 2 anesthesia followed by cervical dislocation, and blood and ovaries were collected.
Histological Evaluation of Follicular Atresia
Ovaries were fixed in Bouin solution for 24 h and transferred to 70% ethanol. After fixation, the tissues were dehydrated, embedded, serially sectioned (5 lm), mounted on glass slides, and stained with hematoxylin and eosin. Every 12th section was used to count atretic follicle numbers to avoid duplicate counting [42, 43] . Moreover, those follicles with intact oocytes were included in the counting. Ovaries from at least 10 or 12 pups were included in EDARAVONE PROTECTS THE OVARY FROM CrVI TOXICITY the study. Atresia of primordial, primary, secondary, and antral follicles was counted separately from that of both the ovaries. Because CrVI induced atresia of follicles in all developmental stages, the numbers of different classes of atretic follicles were added together and expressed as percentages. The criteria to identify atretic follicles was according to Osman [44] and Borgeest et al., [45] as follows: degenerative changes in the GC layer(s), which shows cell shrinkage, pyknosis, and karyorrhexis, and/or degenerative changes in the oocyte such as the breakdown of the nuclear membrane with oocyte fragmentation. Antral follicles were considered atretic if they contained disorganized GCs with at least 20 apoptotic bodies in the GC layer(s).
TUNEL Assay on Paraffin-Embedded Tissue Sections
Paraffin-embedded tissue sections were deparaffinized in xylene and used for TUNEL assay using a TUNEL assay kit (Roche Applied Science) as described previously [16] .
Immunohistochemistry
Paraffin sections from the ovary were fixed in 4% buffered paraformaldehyde (PFA) (6 g PFA, 325 mg NaOH, 15 ml 103 PBS in 100 ml diethyl pyrocarbonate-treated double-distilled H 2 O, pH 7.2) for 4 h at 48C and processed using Vectastain Elite ABC kit (Vector Laboratories). An avidin/ biotin-based peroxidase system was used to detect the biotinylated secondary antibody and the sections were developed using the chromogen 3-amino-9-ethylcarbazole, a peroxidase substrate that produces an insoluble end product that is red in color and observed visually, and quantified using a semiquantitative method (Image ProPlus software; Media Cybernetics, Inc.) [46] . The intensity of staining for each protein was quantified on the oocytes, GCs, and theca cells (TCs) from 10-12 sections; sections were at least 100 lm apart from each other. The average staining intensity of multiple follicles was calculated. Details of primary antibodies, secondary antibodies, dilutions, host species, immunogen, and percentage of homology with rats and mice are given in Supplemental Table S1 .
Measurement of Oxidative Damage in the Ovary
Oxidative damage was measured by estimating the levels of H 2 O 2 and lipid peroxide (LPO) in the ovary as described [16] . Briefly, ovaries were dissected out and homogenized in 50 mM Tris-HCl buffer, pH 7.5, and centrifuged at 10 000 3 g for 15 min. The supernatants were used for the assay. Details of all the assay kits used in the current study are given in Supplemental Table S2 .
Measurement of AOX Enzymes
Activities of Sod1, Cat, Gpx1, and glutathione reductase (Gsr) were estimated in the ovaries of F1 offspring using commercial kits (Cayman Chemical). Ovaries were dissected out and homogenized in 50 mM Tris-HCl buffer, pH 7.5, and centrifuged at 10 000 3 g for 15 min. The supernatants were used for the assay as we previously described in detail [16] .
Measurement of Steroid Hormones
Serum levels of steroid hormones E 2 , testosterone (T), and progesterone (P4) were estimated in F1 female pups on PND 25 using ELISA kits (DRG Diagnostics) according to the manufacturer's instructions. The sensitivities of the assays for E 2 , T, and P4 were 9.0 pg/ml, 0.06 ng/ml, and 0.04 ng/ml, respectively. The intra-assay and interassay coefficients of variation ranged from 4.0% to 7.3%. 
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Statistical Analyses
Dose-response relationships were analyzed by repeated measures of multivariate ANOVA. Least-squares regression analysis was used to determine effects of treatment, dose, and treatment 3 dose interactions. All other numerical data were subjected to one-way ANOVA to detect the effects of treatment and dose interactions. The Tukey-Kramer HSD test was used to adjust for multiple pair-wise comparisons of means. We took the nested structure into account in the design. Mixed-models analysis was used to account for any correlation between the results of pups from the same dam. Mixed models were used to model both fixed effects (in this case treatment) and random effects (in this case dams and pups) [47] . Statistical analyses were performed using general linear models of Statistical Analysis Systems (SAS) and P , 0.05 was considered significant.
RESULTS
In Vivo Studies
Cr Increased Follicular Atresia and Apoptosis of Follicular Cells and Decreased Steroid Hormones and EDA Inhibited Cr Effects. A dose-response study was performed with CrVI doses of 5, 10, 25, 50, 100, and 200 ppm. CrVI significantly (P , 0.05) increased the percentage of atretic follicles with degenerated oocytes and GCs with pyknotic nuclei. CrVI increased apoptosis of oocytes and GCs in a dosedependent manner based on TUNEL staining (Fig. 1, A-F ; TUNEL staining for 100-and 200-ppm CrVI doses is not shown). Moreover, CrVI increased follicle atresia in a dosedependent manner (Fig. 2A) . CrVI significantly (P , 0.05) delayed the onset of puberty and decreased E 2 , T, and P4, and EDA inhibited the effects of CrVI on E 2 , T, and P4 (Fig. 3, A-D) .
EDA Mitigated CrVI-Induced Increase in Cleaved Caspase-3 and Decrease in Bcl2 and Bcl2l1 in the Ovary. CrVI increased the expression of cleaved caspase-3 (Casp3) in the oocytes, GCs, and TCs of the ovary, compared to control. Casp3 was barely detected in the control ovary, and CrVI upregulated cleaved Casp3 expression. Casp3 expression was highest in TCs and moderate in oocytes and GCs. EDA mitigated CrVI-induced increase in cleaved Casp3 expression (Fig. 4) . In control rats, Bcl2 was abundantly expressed with the following order of intensity in different cell types: oocytes . GCs and . TCs. CrVI significantly (P , 0.05) decreased expression of Bcl2 compared to control. EDA mitigated the CrVI-induced decrease in Bcl2 (Fig. 5) . Bcl2l1 was very abundantly expressed in the oocytes and GCs and moderately expressed in TCs. CrVI significantly decreased expression of Bcl2l1 compared to control. EDA mitigated the CrVI-induced decrease in Bcl2l1 (Fig. 6) .
EDA Mitigated Cr-Induced Increase in Oxidative Stress and Decrease in AOX Enzymes in the Ovary. CrVI significantly (P , 0.05) increased LPO and H 2 O 2 levels in the ovary and EDA inhibited CrVI-induced oxidative stress (Fig. 7, A and B) . CrVI decreased activity of AOX enzymes Sod1, Cat, Gpx1, and Gsr in the ovary of F1 rats, and EDA inhibited the adverse effects of CrVI on all of these enzymes (Fig. 7, C-F) .
E2 Treatment Restored CrVI-Induced Decrease in the Expression of AOX Enzymes in the Ovary. CrVI significantly EDARAVONE PROTECTS THE OVARY FROM CrVI TOXICITY decreased Gpx1 in the oocytes, GCs, and TCs. E 2 upregulated Gpx1 in the oocytes compared to both control and CrVI treatment (Fig. 8) . Interestingly, Cat was highly expressed in the follicular fluid and moderately expressed in the basal membrane of the oocytes as well as GCs. CrVI significantly decreased Cat in the oocytes and GCs. Moreover, E 2 caused a shift in the expression pattern of Cat in the ovary. E 2 increased the expression of Cat in the theca interstitial cell compartments in the ovary compared to both control and Cr groups (Fig. 9) . In control ovaries, Prdx3 was very abundantly expressed in the granulosa lutein cells of the corpus luteum (CL), and very minimally expressed in the follicular compartments. CrVI downregulated Prdx3 expression in the CL, and E 2 mitigated the effects of CrIII (Fig. 10) . In the control ovary, Txn2 was abundantly expressed in the follicular fluid. CrVI significantly (P , 0.01) decreased Txn2. E 2 significantly upregulated Txn2 in the follicular fluid, GCs, and basal membrane of the oocyte compared to both control and CrVI (Fig. 11) .
DISCUSSION
The current studies clearly indicate that maternal exposure to CrVI accelerated follicular atresia in PND 25 F1 offspring in a dose-dependent manner. Our previous study indicated that Cr decreased the number of healthy primordial, preantral, and antral follicles [26] . EDA effectively protected the ovaries of the F1 offspring from CrVI-induced increase in follicle atresia. CrVI increased cleaved Casp3 in the ovary. Our recent report also indicated that prenatal exposure to 25 ppm CrVI during the organogenesis window (Gestational Day 9.5-14.5) significantly upregulated cleaved Casp3 and apoptosis of germ cells and somatic cells on PND 1, whereas it was not detectable in the control ovary [48] . Therefore, Casp3-mediated cell death may be one of the key mechanisms for CrVI-induced increase in apoptosis in the ovarian cells followed by follicle atresia. Interestingly, EDA mitigated CrVI-induced increase in Casp3 expression. Earlier findings indicate that elevation in blood levels of E 2 , T, and P4 precede pubertal onset monitored by vaginal opening [49] . Endocrine disruptors such as lead [50] and atrazine [51] are known to delay pubertal onset through a decrease in E 2 levels. In accordance with these studies, the current study also indicates that CrVI decreases levels of E 2 , T, and P4, accompanied by a delay in pubertal onset.
Our previous study indicated that CrVI induced selective subcellular translocation of Bcl2 and Bcl2l1 from mitochondria to cytoplasm in primary cultures of GCs. In contrast, CrVI increased translocation of Bad from cytoplasm to mitochondria, induced apoptosis, and accelerated follicular atresia [27] . Bcl2 has been associated with resistance to apoptosis in a variety of mammalian systems [52] [53] [54] . Deletion of antiapoptotic Bcl2 results in fewer oocytes and primordial follicles at 6 wk of age [55] . Bcl2 family members Bcl2, Bcl2l1, Bax, and Bad proteins are the key mediators of the intrinsic apoptotic pathway in the ovary [56, 57] . Therefore, the current study suggests that CrIII-induced reproductive failure may be due to increased cell death and follicular atresia mediated through STANLEY ET AL. 8 Article 12
Casp3, as well as a decrease in cell survival/antiapoptotic machinery such as Bcl2 and Bcl2l1.
In the cellular reduction of CrVI, a spectrum of ROS (O 2 À , H 2 O 2 , and OH) is produced. Once inside the cells or in body fluids, most CrVI is converted to CrIII [22] . Enormous amounts of free radicals are produced during this reduction/detoxification process that alter redox balance and increase oxidative stress. Whereas CrVI enters cells by facilitated transport, CrIII enters cells by passive diffusion or phagocytosis of precipitates, resulting in much lower uptake [58, 59] . However, Sayato et al. [60] demonstrated the comparative metabolic fate of labeled Cr chloride (CrIII) and sodium chromate (CrVI) and interaction of these compounds in rat liver and blood after their oral and intravenous administration. Gastrointestinal absorption of both the compounds was below 1% of the oral dose. Studies in mice and yeast indicate that CrIII causes more damage to the DNA than CrVI. Once inside the cells or in body fluids, most CrVI will be converted to CrIII. Therefore in the current study, even though dams received CrVI, F1 pups received Cr through dam's milk in the form of CrIII. CrIII can be reduced to CrII by biological reductants, and CrII reacts with H 2 O 2 to generate OH, resulting in oxidative stress [61] . Thus, the current study clearly demonstrates a Cr-induced increase in follicular atresia in F1 offspring, mainly through increased oxidative stress and concomitant decrease in AOX enzymes and steroid hormone levels. EDA, being a potent scavenger of free radicals, mitigated Cr-induced follicular atresia, an increase in oxidative stress, and prevented Cr-induced decrease in AOX enzymes. E 2 plays important roles in preventing oxidative stress [62] . E 2 depletion leads to apoptosis and DNA damage as well as elevated oxidative stress in the lymphocytes of rats, which is reversed by supplementing E 2 [63] . E 2 supplementation reverses the age-related depletion of AOX enzymes and increase in free radicals in rat liver [64] . Therefore, the current study suggests that the decrease in steroidogenesis due to increased follicular atresia may predispose the ovary to decreased AOX enzyme gene transcription and activity, resulting in oxidative stress. On the other hand, decreased AOX enzyme levels may also have indirectly contributed to the decrease in steroidogenic machinery and diminished steroidogenesis. In order to evaluate whether decreased E 2 levels contributed to the depletion of AOX enzymes and to investigate whether CrVI-induced AOX enzyme depletion could be restored by supplementing E 2 , Cr-exposed rats were treated with E 2 for a period of 2 wk. Protein expression of key cytosolic AOX enzymes Gpx1 and Cat along with the mitochondrial AOX enzymes Txn2 and Prdx3 was detected in control ovaries, and Cr significantly decreased the expression of Gpx1, Cat, Txn2 and Prdx3, whereas treatment with E 2 restored Cr-induced depletion of these enzymes. Gpx1 and Txn2 levels were higher than the control in E 2 -treated groups. Mitochondria-specific Txn2 and Prdx3 are the major EDARAVONE PROTECTS THE OVARY FROM CrVI TOXICITY regulators of mitochondrial H 2 O 2 concentration and apoptosis, and Gpx1 is a major cytosolic isoform in mammalian cells that plays a critical role in the protection of cells against oxidative damage by H 2 O 2 . It has been shown that aging decreased mRNA expressions of mitochondrial AOX genes Prdx3 and Txn2 and increased oxidative stress markers in mouse ovary, indirectly indicating an association between ovarian steroids and redox balance [65] . E 2 increased glutathione content in human erythrocytes treated with CrVI [66] . E 2 supplementation increased AOX enzymes in the liver and brain of ovariectomized rats [67] . E 2 at nM and lM concentrations decreased lipid peroxidation caused by sodium fluoride in mitochondria isolated from human placenta [68] . The oocyte is one of the cells that express the highest levels of glutathione (;10 mM) [69] . Particularly, the current study showed that E 2 increased Gpx1 in the oocyte and Txn2 in the oocyte and follicular fluid surrounding the oocyte, suggesting an important role of these enzymes in oocyte survival against Cr toxicity.
Prdx3 plays a very important role in the elimination of H 2 O 2 in luteal cells [70] . Prdx3 eliminates H 2 O 2 and reduces the number of OH produced by the Fenton reaction and the subsequent tissue injury [71] . Interestingly, Prdx2À knockout mice were shown to have more severe tissue damage and higher mortality rates than controls, even when Cat and Gpx proteins were normally expressed [71] . E 2 inhibits peroxidation of low-density lipoprotein in postmenopausal women [72] . We have found that Prdx3 protein levels were highly expressed in granulosa lutein cells, but not in the other cell types in the follicular compartment, suggesting an important role of Prdx3 in particular in CL survival and function. Thus, the current data indicate that Cr-induced decrease in E 2 may be one of the mechanisms for the depletion of AOX enzymes and increased ROS, and E 2 plays an AOX role in the ovary to protect against Cr toxicity.
EDA is a potent free radical scavenger [31, 37, 73] . Its protective effects have been studied in several pathological conditions [28, 31, 32, 34, 36, 37, 41, 74, 75] . For example, EDA reduces the steroid-induced osteonecrosis in rabbits by suppressing the accumulation of lipid peroxidative products and oxidative DNA damage [76] ; EDA has preventive and curative effects on diabetic neuropathy [77] ; and EDA reduces cytochrome c release and increases the expression of Bcl2 in myocardial infarction [74] . It protects hepatocytes from Fasinduced mitochondrial-dependent apoptosis by regulating mitochondrial Bcl2l1 and Bax in mice with fulminant hepatic failure [75] . EDA attenuates cisplatin-induced renal dysfunction, mitochondrial damage, real protein oxidation, and tubular apoptosis in rats [41] . In spite of its importance, only two studies have been conducted so far to study the effect of EDA on the ovary: 1) EDA protects the ovary from experimentally induced ovarian torsion/detorsion ischemia/reperfusion injury [78] ; and 2) prophylactic treatment with EDA prevents ischemia/reperfusion-induced ovarian damage during pneumoperitoneum in an experimental rat model [79] . This is the first study on the protective effect of EDA against any toxicant. STANLEY ET AL.
